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Inhaled corticosteroids (ICS) are frequently used in the treat ment of patients with asthma (1-3). In current guidelines, treat ment of patients with severe asthma with dosages as great as 2,000 |j,g daily is recommended (1,2). These dosages are associated with systemic effects such as a decrease in morning cortisol (3) and adverse effects on markers of bone metabolism.
Fluticasone propionate (FP) is a new ICS with a higher topi cal anti-inflammatory effect in humans than ICS such as beclomethasone dipropionate (BDP) (4). In clinical studies FP is as potent as the double dose of BDP with regard to bronchial hyper responsiveness, FEVlf peak expiratory flow rate (PEFR), and symptom scores (5-7). In addition, FP has negligible oral bioavail ability (8) . However, as the majority of the systemic available dose will reach the bloodstream after absorption from the lungs, assessing the overall systemic activity remains necessary. Data currently available suggest that in equipotent dosages, FP may have less effect on the hypothalamic-pituitary-adrenal (HPA) axis than BDP (5, 6).
The other above-mentioned potentially serious side effect of ICS concerns bone quality and metabolism. Osteoporosis may
METHODS

Patients
Thirty nonsmoking patients with asthma 18 to 55 yr of age (mean, 30.3 yr) were recruited from the out-patient department. Their characteris tics are summarized in Table 1 . A ll women were premenopausal. No pa tient had any other pulmonary disease or serious concomitant disease and none reported bone fractures in the preceding 3 yr or had reported spontaneous fractures at all. All patients had been receiving regular treat ment with BDP or budesonide for an average of 5.4 yr (range, 0.3 to 16 yr) with an average daily dose of 790 p.g (range, 400 to 1,600 |xg). None had used OCS as maintenance treatment, i.e., continuously for more than 3 mo, but 13 patients had needed short courses o f OCS in the past to treat exacerbations. No patient had used OCS in the preced ing 6 mo. The study was approved by the Nijmegen University medical ethics committee. All study subjects gave written informed consent be fore entry into the study.
Protocol
The study was a randomized, crossover trial consisting of a 3-wk single blind washout (placebo) period before each of the two 6-wk double blind active treatment periods (flow-chart in Figure 1 ). Treatment ran domization was performed prior to the first placebo period, but at the 5.4 ± 4.0 13 1.5 ± 3.4
Definition of abbreviations: PEFR = peak expiratory flow rate; ICS = inhaled cortico steroids; OCS = orally administered corticosteroids. * Values are m e a n ± S D .
1,25-dihydroxyvitamin D3 (l,25[OH]2D3) were determined in b lo o d . As markers of bone formation, serum alkaline phosphatase (A P), osteocal cin (OC), and carboxyterminal propeptide of type 1 procollagen (P1CP)
After First Placebo
were measured (15) (16) (17) . Markers of bone resorption included carboxy terminal cross-linked telopeptide of type 1 collagen (1CTP) a n d urin ary calcium, hydroxyproline (HP), and deoxypyridinoline (D p d ) cross links (15, 16) . Ca, P, AP, and creatinine (Cr) were automatically determined on a Hitachi 747 automatic analyzer (Boehringer, Mannheim, G erm any) ac cording to standard hospital procedures. Blood samples for measure ments o f OC, P1CP, 1CTP, and l,25(OH)2D3 were im m ediately cen trifuged and kept at -20° C until assayed later. OC was measured using a commercial OSTK-PR radioimmunoassay (Cis, Gif sur Yvette, France); intra-assay coefficient o f variation (CV) was 3.0 to 3.6% and interassay CV was 5.5 to 6.6% at serum levels of 0.22 to 4.26 nm ol/L. P 1 C P and 1CTP were measured using a radioimmunoassay kit (Orion D iagnostics, Espoo, Finland); for P1CP intra-assay CV was 2.1 to 2.7% and interas say CV was 4.1 to 6,6% at levels of 103 to 216 ng/L; for 1CT P intra assay CV was 6.2% and interassay CV was 7.9% at levels o f 3.8 and 3.3 ng/L, respectively. 1,25 (OH)2Dj radio receptorassay was perform ed after diethylether extraction and paper chromatography o f the samples.
Tritriated vitamin D3 was added to 1 to 2 ml of plasma prior to extrac tion. Extracts were dried under nitrogen and chromatographed (intra assay CV, 10.5%; interassay CV, 11.5% at levels of 93 and 103 p m o l/L , respectively) (18) . Blood samples for plasma-intact PTH were im m e d i ately placed on ice and determined by means of an im m unoradiometric assay (Nichols Institute, Wychen, the Netherlands); intra-assay C V was 
Statistical Analysis
The best of three PEFR measurements on a mini-Wright peak flow mea first-and second-order carryover effect can be distinguished, o f which ter in the morning and evening before medication was recorded.
Laboratory measurements. On the mornings of Visits 1 to 4, a veonly the latter may interfere with the treatment effect. Therefore, a p value > 0.01 was taken for the second-order carryover effect to supposnous blood sample and a urine sample were taken during the first 2 h edly exclude any influence on treatment effects. The first-order carryover after initial voiding after a 12-h overnight fast. Blood and urine were effect was tested by comparing the differences of Measurements 3 and taken between 7:00 and 9:00 a .m. (for individual patients always at the 1 between treatment-order groups. The second-order carryover effect same time) prior to lung function measurements. To assess effects on was tested by comparing the sum of two differences (i.e., 2 m in u s 1 and adrenal function, morning plasma cortisol was determined using an in-4 minus 3) between treatment-order groups. In this way a necessary adhouse radioimmunoassay involving heat inactivation of corticosteroidjustment was made for the unbalance present in several variables at Meabinding globulin. For the analysis o f calcium and phosphate metabosurement 1 in order to prevent this unbalance from interfering w ith the lism, calcium (Ca), phosphate (P), parathyroid hormone (PTH), and carryover completed the study. Their characteristics are summarized in Ta-TABLE 2 ■TREATMENT-EFFECT TWO (Table 4) . Direct treatment-effect compariwith FP.
Differences in Treatment
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Calcium metabolism
The p values of first-and second-order carryover effects of Täble 2 line/creatinine ratio showed a second-order carryover effect and son between FP and BDP showed to be significantly different was excluded from further analysis. There were no carryover ef~ in effects on OC and P1CP (Table 2) . fects significant at 10% for the other variables studied. No sig nificant differences existed between the two baseline values (Mea surements 1 and 3).
Clinical Efficacy
Both FP and BDP caused a significant increase in FEV, and morning and evening PEFR. W ith FP the A-effect on FEV, BDP were found (Thble 2). was 0.45 ± 0.12 L, and with BDP it was 0.34 ± 0.09 L (both
Bone Resorption
1CTP decreased after BDP (-11.5 ± 8.2%; p < 0.05), but not after F P (-3 .8 ± 3.8% ;p = 0.18)(T^ble3). Urinary Ca/Cr and Dpd/Cr did not change after treatment. 
Adrenal Function
Mean cortisol values changed from 0.64 ± 0.06 to 0.61 ± 0.06 |amol/L after FP (p = 0.42) and from 0.60 ± 0.06 to 0.59 ± but not after BDP (A-effect, -10.7 ± 6.0 L/min; p 0.14).
the cortisol level fall below the lower limit of normal in our lab oratory (0.19 |imol/L). There were no significant differences in A direct comparison of the treatment effects showed no signifitreatment effects between FP and BDP (Table 2 ). cant differences between FP 750 fxg daily and BDP 1,500 jug daily.
Calcium, Phosphate, and Regulating Hormones
Serum Ca, P, PTH, and l,25(OH)2D 3 were not significantly changed by FP and BDP (Table 3) . After both ICS, Ca and P changed less than 1 and 3% from baseline, respectively. PTH increased by 6,3 ± 6.0% after FP and by 7.1 ± 5.6% after BDP. l,25(OH)2D 3 increased by 18.6 ± 8.3% after FP and by 11.3 ± 6.6% after BDP. No significant differences between the treat ment effects of FP and BDP were found (Table 2) .
Bone Formation
V A P did not change after FP and BDP (Table 3) . OC and P1CP, however, were significantly decreased after BDP, but not after FP. OC decreased by 18.5 ± 3.9% after BDP (p < 0.001) and by 5.5 ± 3.6% after FP (p = 0.16). P1CP decreased by 21.9 ± 6.8%
DISCUSSION
This crossover study in asthmatic patients shows that BDP 1,500 M -g daily for 6 wk caused a significant depression of OC and P1CP, both markers of bone formation. In contrast, FP did not change any variable of bone formation. Both FP and BDP did not af fect indices of bone resorption, calcium metabolism, or cortisol. With regard to clinical efficacy, FP 750 M -g daily was as effective as the double dose of BDP on FEV, and PEFR.
As one o f the important side effects of corticosteroids may be osteoporosis, we measured in this study effects of FP and BDP on biochemical markers of bone metabolism. OC is a very sensi tive marker o f osteoblast activity, as most serum O C originates from new cellular synthesis (17) . OC is a specific marker of bone formation in processes with uncoupled bone formation and re sorption, as is the case in glucocorticoid-induced osteoporosis 
A-EFFECTS OF FP A N D BDP ON BONE j ( w r ] --
. P1CP specifically measures collagen type 1 synthesis, the reflected in the concentration of crosslinks, and Dpd is more spemajor collagen product produced by osteoblasts. It is cleaved cific for osseous tissue than are pyridinoline crosslinks (16) . As from collagen type 1 during its processing to fibrils (one liber-1CTP does not change to the same extent as P1CP in situations ated propeptide for every formed collagen molecule: 1:1). It rein which the metabolic rate of trabecular bone is affected, as is fleets the changes in whole bone tissue. P1CP decreases in therathe case with glucocorticoids, a net formation of type 1 collagen pies that slow the metabolic rate of bone as glucocorticoids (15, (P1CP/1CTP) cannot be calculated. 16). Markers of bone resorption included 1CTP and Dpd crossBiochemical markers do, however, possess some links (15, 16) . 1CTP measures the degradation of mature type falls. Osteocalcin is regulated at the gene level by 1,25-vitamin D; I collagen (containing pyridinoline crosslinks). 1CTP increases therefore, osteocalcin may be elevated in patients with abnorin diseases that degrade the surface (cortical part) o f bone tissue mal serum 1,25-vitamin D levels. Osteocalcin is cleared by the (e.g., rheumatoid arthritis, bone metastasis), but it changes only kidneys, so patients with renal failure can exhibit increased leva little when trabecular bone is affected as is the case with glucoels of osteocalcin without a concomitant increase in bone forcorticoid therapy (15) . Changes in trabecular bone are better mation. Moreover, osteocalcin exhibits a marked diurnal varia- tion, and the serum antigen loses its immunologic activity at room No increase in parameters of bone resorption were found in temperature or by repeatedly freezing and thawing (15, 16) . P1CP the present study. This is in line with the findings in most studies also exhibits diurnal variation (15, 16) . Dpd is now considered the best available method for bone resorption, although the con centration of crosslinks is not invariant in bone, which could influence urinary concentration. In addition, Dpd has a marked on ICS (9, 12, 13, 26, 27) . Only Ali and coworkers (10) showed an increase in Ca/Cr and HP/Cr ratios after treatment with 2,000 |ig BDP/d. The statistical analysis in their open study in eight healthy subjects, however, raises questions about its interpretadiurnal variation (16) . In the present study, all samples were imtion. In the present study, 1CTP decreased after treatment with mediately determined or frozen and processed at once to exclude BDP (-11.5%, p < 0.05). No differences in direct treatment comany influence of laboratory handling. Urinary samples were taken parison between FP and BDP were present. Sorva and coworkafter an overnight fast to correct for dietary sources of hydroxyers (28) also showed in 14 children a decrease in 1CTP after 1 mo proline and corrected for creatinine. Finally, to correct for diurof treatment with budesonide 800 fig/mVd. Deoxypyridinoline nal variation, samples were always taken at the same moment in individual subjects. crosslinks in urine, however, did not change. These results are in line with the data from a recent cross-sectional study, showOsteoporosis may affect as much as 40% of patients receiving no differences in (deoxy)pyridinoline crosslinks between asthing maintenance treatment with OCS (20) . OCS inhibit the inmatic patients without ICS and patients treated with ICS and testinal absorption of Ca and P, and they may increase urinary occasionally OCS (27) . Altogether, these findings indicate that in general ICS do not increase bone resorption. Changes in Ca, P, PTH, or l,25(OH)2D 3 did not occur. Previ ous short-term studies with ICS did not show adverse effects on crease in AP, OC, and P1CP) (13, (21) (22) (23) ) and possibly also inCa or P in adults either, even with doses of 2.4 and 3.2 mg/d (9, 12).
Ca excretion. The resulting decrease in serum Ca evokes second ary hyperparathyroidism, reflected in increased serum PTH (21) . Furthermore, OCS decrease bone formation (reflected in a decrease bone resorption (reflected in an increase in Ca/Cr and HP/Cr) (21, 23). These changes lead to secondary osteoporosis and a rise in (nontraumatic) fracture incidence (20, 21, 24) . OCS in doses of 7.5 mg/d or more cause significant loss of trabecular dependent decrease in morning cortisol levels has been reported, Morning cortisol, used as a marker of adrenal suppression, did not change. From dosages of 1,000 \ig/d ICS on, a dosebone in most patients, but lower doses of OCS may also have adverse effects (25). Furthermore, data suggest that bone loss is most pronounced in the early weeks of OCS therapy, with sub sequent slowing during prolonged treatment (25).
ICS interact with the same glucocorticoid receptors, and they would therefore be expected to act in a similar way after systemic but at daily doses of approximately 1,500 txg (as in the present study), the majority of studies, as recently reviewed by Barnes and Pedersen (3), still did not show significant changes. Most studies (including ours) did, however, measure only morning se rum cortisol, an insensitive method of detecting changes in HPAaxis. The study by Nicolaizik and coworkers (29) showed that absorption. Several short-term studies with ICS, both in healthy at 8:00 a .m . cortisol did not change with ICS, but 24-h urinary subjects and in patients, have shown a decrease in OC levels af ter treatment, indicating effects of ICS on bone formation (11-14, cortisol levels were significantly depressed. Furthermore, our study lasted for only 6 wk, and patients inhaled ICS without a 26). Pouw and coworkers (11) showed that 2,000 |j,g BDP daily spacer. This also may have resulted in our inability to detect any in healthy volunteers decreased OC by 30% after 8 d o f treat ment and by 21% after 2 wk of treatment. The present study confirms the effect of BDP on parameters of bone formation. Both OC and P1CP decreased significantly by 19 and 22%, respecchanges. Nevertheless, two large studies, both with more than 150 patients, did report significant differences between FP and BDP on HPA-axis, showing an increase in cortisol after 200 and 1,000 ng FP daily for 4 and 6 wk, respectively, in contrast to a tively, from baseline after 1,500 M -g BDP daily for 6 wk, suggest-(nonsignificant) decrease after 400 and 2,000 |xg BDP (5, 6). ing an ongoing depressing effect on bone formation. O C and P1CP returned to baseline values after 3 wk of withdrawal (Ta ble 4), which suggests that effects on these indices of bone for mation are directly related to the treatment with BDP. In conChanges in adrenal function are not necessarily related to changes in indices of bone formation. Changes in bone metabo lism can be detected from 400 |xg BDP daily on (14) , in contrast to an absence of significant changes in cortisol levels at doses trast, a clinically equipotent dose of FP did not change these below 800 to 1,000 M -g BDP daily (3). Kiviranta and Tlirpeinen parameters of bone formation in the same patients. Finally, as in most studies (12, 13, 26, 27) , both ICS showed no effects on AP levels. (30) also reported effects on carbohydrate metabolism without any significant effect on the HPA-axis after treatment with 2,000 (j,g BDP daily for 5 mo. Apparently, the organs involved may have a different sensitivity for ICS. The present investigation was performed using a crossover de sign, which has the potential disadvantage of a carryover effect. A carryover effect is statistically detectable only with low power. Therefore, a p > 0.1 was taken for the second-order carryover effect to exclude any influence on treatment effects. Furthermore, after the second washout period (Measurement 3), all but uri nary hydroxyproline/creatinine ratio returned to pretreatment lev els (Measurement 1) (see Tkble 4). Therefore, carryover effects are not likely to have affected the outcome in the present study both from a statistical point of view and in terms of clinical rele vance.
Another point of discussion is that our patients did not use a spacer device to inhale their ICS. The use of a spacer may in crease lung deposition, and the fraction deposited in the intrapulmonary airways is likely to be absorbed in active form into the systemic circulation (3). There is no evidence for local metabo lism of FP in the lung. Therefore, the majority will reach the bloodstream after absorption from the lungs. It is possible that the use of a spacer could have given different systemic effects. Nevertheless, the present study compared directly two types of ICS, using the same method of administration, making direct comparison possible. All patients were fully skilled in using a M D I device, and their technique was checked at every visit. A ll patients improved clinically to a great extent. The use of a spacer is not likely to have changed the observed differences between the two drugs.
Finally, the relevance of effects of ICS on bone metabolism are debatable. Kerstjens and colleagues (26) reported that long term treatment with ICS did not affect biochemical markers of bone metabolism. P1CP and 1CTP remained unchanged after 2.5 yr of treatment with 800 fig BDP daily. Long-term studies with higher dosages of ICS have not been reported to our knowl edge. The clinical diagnosis of osteoporosis requires the pres ence of at least one relatively atraumatic fracture (31). Until now no rise in fracture incidence has been reported in patients receiv ing long-term ICS treatment. The risk o f fracture may be assessed by in vivo measurements of bone density. In a prospective study for 1 yr in 63 women who had undergone bilateral oophorec tomy, there were high correlations between biochemical markers (bone-specific AP and urinary HP) and the change in cortical area per year (32). Furthermore, in a cross-sectional study of 214 women who had undergone bilateral oophorectomy up to 12 yr previously, changes in bone balance as estimated by differences in biochemical markers of bone formation (bone-specific AP) and bone resorption (urinary HP) paralleled up to 12 yr, the mea sured changes in bone density (31), confirming the validity o f biochemical markers of bone metabolism.
Decreases in bone density have been suggested after treatment with ICS (27, 33). Packe and coworkers (27) , measuring density of the lumbar spine by quantitative single energy computed tomography, showed a mean bone density of 160.4 mg/ml in a group of asthmatics treated without ICS compared with 127.5 mg/ml in a matched group treated with > 1,000 ng BDP and courses of OCS for at least 1 yr. In a group o f patients treated with ICS for at least 3 mo, Ip and colleagues (33) showed with dual energy X-ray absorptiometry that bone mineral density was decreased at the hip and the lumbar area o f the spine in compar ison with a matched group of healthy subjects. In these studies it is impossible to quantify the contribution of previous OCS treatment to loss of bone density. This, however, may be the most important factor influencing bone density among other factors such as increased age, inactivity, smoking, malnutrition, meno pausal status, and genetic predisposition. In order to avoid these potential sources of bias with respect to biochemical markers of bone turnover, the present study was performed in a crossover design in, besides their asthma, healthy premenopausal nonsmok ing subjects.
With regard to the higher dosages, advocated by the guide lines on the management of asthma (1, 2), it cannot be excluded that they have adverse effects on bone in the long term. In this respect, the lack of short-term effects on bone metabolism by FP 750 |ig/d, in contrast to a clinically equipotent dose of BDP 1,500 fxg/d, may be of potential interest in the long term. 
